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Background: “Repair” of many congenital cardiac defects requires the use
of conduits to establish right ventricle to pulmonary artery continuity. At
present, available homografts or prosthetic conduits lack growth potential
and can become obstructed by tissue ingrowth or calcification leading to the
need for multiple conduit replacements. Tissue engineering is an approach
by which cells are grown in vitro onto biodegradable polymers to construct
“tissues” for implantation. A tissue engineering approach has recently been
used to construct living cardiac valve leaflets from autologous cells in our
laboratory. This study assesses the feasibility of a tissue engineering
approach to constructing tissue-engineered “living” pulmonary artery
conduits. Materials and methods: Ovine artery (group A, n 5 4) or vein
(group V, n 5 3) segments were harvested, separated into individual cells,
expanded in tissue culture, and seeded onto synthetic biodegradable
(polyglactin/polyglycolic acid) tubular scaffolds (20 mm long 3 15 mm
diameter). After 7 days of in vitro culture, the autologous cell/polymer
vascular constructs were used to replace a 2 cm segment of pulmonary
artery in lambs (age 68.4 6 15.5 days, weight 18.7 6 2.0 kg). One other
control animal received an acellular polymer tube sealed with fibrin glue
without autologous cells. Animals were sacrificed at intervals of 11 to 24
weeks (mean follow-up 130.3 6 30.8 days, mean weight 38.9 6 13.0 kg) after
echocardiographic and angiographic studies. Explanted tissue-engineered
conduits were assayed for collagen (4-hydroxyproline) and calcium content,
and a tissue deoxyribonucleic acid assay (bis-benzimide dye) was used to
estimate number of cell nuclei as an index of tissue maturity. Results: The
acellular control graft developed progressive obstruction and thrombosis.
All seven tissue-engineered grafts were patent and demonstrated a nonan-
eurysmal increase in diameter (group A 5 18.3 6 1.3 mm 5 95.3% of native
pulmonary artery; group V 5 17.1 6 1.2 mm 5 86.8% of native pulmonary
artery). Histologically, none of the biodegradable polymer scaffold re-
mained in any tissue-engineered graft by 11 weeks. Collagen content in
tissue-engineered grafts was 73.9% 6 8.0% of adjacent native pulmonary
artery. Histologically, elastic fibers were present in the media layer of
tissue-engineered vessel wall and endothelial specific factor VIII was
identified on the luminal surface. Deoxyribonucleic acid assay showed a
progressive decrease in numbers of cell nuclei over 11 and 24 weeks,
suggesting an ongoing tissue remodeling. Calcium content of tissue-
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engineered grafts was elevated (group A 5 7.95 6 5.09; group V 5 13.2 6
5.48; native pulmonary artery 5 1.2 6 0.8 mg/gm dry weight), but no
macroscopic calcification was found. Conclusions: Living vascular grafts
engineered from autologous cells and biodegradable polymers functioned
well in the pulmonary circulation as a pulmonary artery replacement. They
demonstrated an increase in diameter suggesting growth and development
of endothelial lining and extracellular matrix, including collagen and
elastic fibers. This tissue-engineering approach may ultimately allow the
development of viable autologous vascular grafts for clinical use. (J Thorac
Cardiovasc Surg 1998;115:536-46)
Children who undergo ventricle–pulmonary artery(PA) connections with either prosthetic or ho-
mograft extracardiac conduits require multiple re-
operations because of conduit failure.1 Biopros-
thetic conduits and allogenic graft replacements
have certain disadvantages that greatly limit their
long-term benefits. These conduits are foreign ma-
terials that lack the ability to grow, repair, or
remodel. More important, they are potentially
thrombogenic and susceptible to infection through-
out their life span. These inherent problems have
significantly limited their durability, especially in the
pediatric age group. The search for an ideal conduit
is still ongoing. In an attempt to overcome the
shortcomings of currently available conduits, we
tested the feasibility of constructing tissue-engi-
neered conduits in lambs with autologous arterial
and venous wall cells containing myofibroblasts and
endothelial cells seeded in vitro onto a synthetic
polyglycolic acid (PGA) fiber matrix. We have pre-
viously reported the feasibility of using the TE
approach to construct heart valve leaflets.2, 3 This
study was carried out to evaluate whether autolo-
gous tissue-engineered conduits could maintain the
pulmonary circulation in a growing lamb model.
Methods
The techniques of cell isolation, culture, cell sorting,
polymer characteristics, and cell seeding were previously
described in detail.4 Briefly, 2 to 3 cm sections of carotid
artery were harvested from 20-day-old lambs (group A,
n 5 4), minced, and cultured in Dulbecco’s Modified
Eagle Medium (Gibco BRL-Life Technologies, Grand
Island, N.Y.) supplemented with 10% fetal bovine serum
(Sigma Chemicals, St. Louis, Mo.) and 1% guinea pig
serum (29.2 mg/ml l-glutamine, 10,000 units/ml penicillin
G sodium, and 10,000 l 3 gm/ml streptomycin (Gibco)
media. In the other three animals (group V), 2 to 3 cm
sections of jugular vein in lambs were harvested and
cultured in the same manner. The media was changed
every 7 days, and in vitro cell growth was assessed
periodically. The explanted tissue culture was placed in a
humidified incubator maintained at 37° C with 5% carbon
dioxide for 6 to 9 weeks. Cell growth from the explants
was observed after several days to form mixed cell popu-
lations of endothelial cells and fibroblasts. The cultured
cells were then labeled with an acetylated low-density
lipoprotein marker (Biomedical Technologies Inc.,
Stoughton, Mass.), which is selectively taken up by endo-
thelial cells through the scavenger pathway. After a 24-
hour incubation period, the cells were sorted into low-
density lipoprotein–positive endothelial cells, and low-
density lipoprotein–negative fibroblasts and smooth
muscle cells with a fluorescent activated cell sorter. En-
dothelial cells were found in 2% to 3% of mixed cell
culture in both groups after 2 weeks in vitro culture. The
tubular tissue scaffold (20 mm long 3 15 mm in diameter)
was composed of a polyglactin woven mesh (Ethicon, Inc.,
Somerville, N.J.) sealed with nonwoven PGA mesh (Al-
bany International Research Co., Mansfield, Mass.) inside
the lumen (Fig. 1). The mesh matrix was greater than 95%
porous before seeding. The scaffold was designed so that
it would be biodegraded over a 6- to 8-week period.5 In
each group, 10 million mixed cultured cells were seeded
onto the polymer. Culture media was changed on a daily
basis. After 7 days, cells became confluent on the polymer
in both groups.
PA replacement. Autologous tissue-engineered con-
duits were implanted into the same lambs from which the
cells had been previously harvested (average age 68.4 6
15.5 days, body weight 18.7 6 2.0 kg). One other animal
received an acellular polymer tube sealed with pasteurized
fibrin glue (Bolheal, The ChemoSero-Therapeutic Re-
search Institute, Japan) consisting of fibrinogen (80 mg/
ml), thrombin (250 units/ml), plasmin inhibitor aprotinin
(1000 KIE/ml), calcium chloride (5.9 mg/ml), and fibrin-
stabilizing factor VIII (75 units/ml). This prevented blood
leaking through the acellular polymer tube.
Anesthesia was induced with 30 mg/kg of intramuscular
ketamine and maintained with continuous infusion of 0.2
mg/kg per minute of propofol. The chest was exposed
through a left thoracotomy at the third intercostal space.
Normothermic femoral arterial and right atrial cardiopul-
monary bypass was established. With the heart beating,
the PA was transected and a 2 cm section of main PA was
resected and replaced with either a tissue-engineered
conduit or a plain polymer conduit with 5-0 monofilament
sutures. All animals received humane care in compliance
with the “Guide for the Care and Use of Laboratory
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Animals” published by the National Institutes of Health
(NIH Publication No. 85-23, revised 1985).
Evaluation of tissue-engineered conduits. After im-
plantation, Doppler echocardiography was used periodi-
cally to evaluate conduit patency and growth potential. All
animals underwent angiography immediately before they
were killed. The diameter of tissue-engineered conduit
was measured angiographically and compared with that of
adjacent native main PA and expressed as percentage of
native PA.
Animals were killed and main PAs were explanted at 75
to 169 days after implantation (average interval after
implantation 125.4 6 20.8 days, body weight 38.6 6 13.9
kg). After the animals were killed, a portion of the
specimen was fixed with 10% formalin for histologic
examination with hematoxylin and eosin or Miller’s elastic
stain. The other portion was immersed in 0.9% saline
solution and immediately processed for collagen, calcium,
and deoxyribonucleic acid (DNA) assays. A 4-hydroxypro-
line assay6 was used to measure the collagen content in
the tissue-engineered conduits. DNA assay7 was used to
determine the cell density in the tissue. The collagen and
DNA content of these constructs were compared with the
native PA of the same animal and expressed as a percent-
age of the native artery. The ortho-cresolphthalein com-
plexon (OCPC) method was used for calcium measure-
ment.8 Additional sections of the conduits were also
stained for factor VIII with immunohistochemical tech-
nique with a monoclonal anti-factor VIII antibody (Bio-
Genex, San Ramon, Calif.).9
Results
Echocardiographic and angiographic findings.
Two weeks after implantation, echocardiography
showed patent conduits in all group A and V
animals. Thrombus formation was identified in the
control animal causing PA stenosis. The echo den-
sity of the conduit was initially higher than native
PA partly attributed to the presence of polymer.
(Fig. 2, a and c). After 10 to 12 weeks, tissue-
engineered conduits showed no evidence of throm-
bus formation or calcification in either group A or
V. In addition, the high-density material in the
conduit wall had disappeared (Fig. 2, b and d). On
angiography, all conduits showed an increase in
diameter compared with that at the time of implan-
tation (Figs. 3 and 4). However, the percentage
diameter remained 95% 6 1.7% in group A and
86.8% 6 2.9% in group V compared with the native
PA, respectively (Fig. 5, a).
Macroscopic findings. The gross appearance of
the tissue-engineered conduits in both group A and
V resembled the native PA, although they were
somewhat thinner (Fig. 6). The control animal was
killed 2 weeks after implantation because of severe
dyspnea and pulmonary stenosis. Progressive throm-
bus formation and contraction of the polymer wall
was found (Fig. 6, e).
Histologic examination. The predominance of
polymer was confirmed histologically in control an-
imals killed 2 weeks after implantation. The speci-
mens from the group A or V showed almost com-
plete disappearance of PGA polymer, and the
tissue-engineered conduit resembled the native pul-
monary vascular cellular architecture. Millers elastic
stain showed evidence of elastic and collagen fiber in
the engineered artery wall (Fig. 7).
Immunohistochemical staining. Factor VIII–
stained endothelial cells were found lining the lumi-
nal surface of the tissue-engineered conduit (Fig. 8)
in six of six conduits (three in group A and three in
group V).
Biochemical examination. The 4-hydroxyproline
assay demonstrated that the tissue-engineered con-
duit contained about 70% collagen content com-
pared with native PA (Fig. 5, b).
Calcium assay. In tissue-engineered conduits,
calcium content was elevated compared with native
PA (group A 5 7.95 6 5.09, group V 5 13.2 6 5.48,
Fig. 1. Polymer scaffold (top, frontal view; bottom, lateral
view) 15 mm in diameter and 20 mm long.
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native PA 5 1.2 6 0.8 mg/gm dry weight), but no
macroscopic calcification was found (Fig. 5, c).
DNA assay. DNA content (cell nuclei density per
gram dry tissue) in the tissue-engineered conduit
was higher than native PA tissue when the animal
was killed (group A, 180.0% 6 50.7%; group V,
148.3% 6 22.3%) (Fig. 5, d).
Discussion
The search for an ideal vascular conduit for use in
children continues because all the current synthetic
or bioprosthetic grafts used clinically are far from
ideal vascular replacements. None have growth po-
tential; therefore durability is limited for growing
children.
All synthetic grafts are thrombogenic to some
extent. Tightly woven grafts have been used in the
past because their low porosity was preferable in
patients given heparin. However, these grafts have
the disadvantage of poor neointima formation and
tissue ingrowth, which promotes calcification. In-
evitably, progressive increases in pressure gradi-
ents develop over time across these conduits, and,
by 10 years all conduits required replacement
when used in the pulmonary circulation in our
institute.1, 10
Homografts currently seem to be the best con-
duits that fulfill the physical and handling require-
ments for applications in pediatric patients with
defects requiring right ventricle to PA connection.
These grafts have been reported to be superior to
other synthetic conduits, but in other reports they do
not seem to offer much advantage over prosthetic
grafts.1, 11 At present, homograft conduits are cryo-
preserved and stored in liquid nitrogen until used.
Cryopreservation has been suggested to preserve
fibroblast viability,12, 13 which might theoretically
result in growth potential and make them less
thrombogenic. Nevertheless, the presence of viable
allograft components may enhance immune rejec-
tion, leading to calcification and subsequent failure.
In addition, homograft donor scarcity remains a
Fig. 2. Echocardiography. a, Group A; 2 weeks after implantation TE conduit still contained high-density
material (polymer). b, Group A: 10 weeks after implantation. TE conduit showed no evidence of stenosis
or dilatation. c, Control; 2 weeks after implantation. Massive thrombus in the conduit. d, Group V; 16
weeks after implantation. TE conduit showed no evidence of stenosis or dilatation or calcification.
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Fig. 3. Pulmonary artery angiography. Arrows indicate tissue-engineered conduit. a and b, Group A. c and
d, Group V.
Fig. 4. Changes in diameter of tissue-engineered conduits and native pulmonary artery (PA). A, group A;
V, group V. The numbers represent the days after implantation.
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significant problem that continues to limit its wide-
spread clinical application.
To overcome these shortcomings, efforts have
been made to develop an ideal, viable, conduit that
should be nonthrombogenic, have growth potential,
and require no additional replacement operation.14-17
The first attempt to create vascular structure from
cellular components was carried out by Weinberg
and Bell.18, 19 They constructed a three-layered
blood vessel model in vitro with collagen matrix as a
scaffold for endothelial cells, smooth muscle cells,
and fibroblasts. However, the collagen matrix was so
distensible that it dilated and ruptured at very low
pressure (,10 mm Hg). Therefore they had to
integrate a Dacron mesh onto the outer layers for
additional support. This concept of a “tissue-engi-
neered blood vessel” has been reported by other
investigators,20-23 but to our knowledge none have
succeeded with in vivo implantation with a com-
pletely bioabsorbable polymer scaffold.
We have applied the methods and principles of
TE in an effort to create viable structures to replace
diseased or deficient natural structures. Our labora-
tory has focused on the use of a biodegradable
polymer scaffold as a cell delivery system. Many cell
types to be used in engineered tissue can be grown
in vitro using tissue culture techniques. Once cells
are attached to a three-dimensional biodegradable
polymer, the resulting tissue construct can be im-
planted in vivo, where the cells continue to grow and
develop a predesigned structure. While the cellular
structure and matrix develop, the polymer degrades,
Fig. 5. Comparison of tissue-engineered conduits between groups. a, Diameter of tissue-engineered
conduit is expressed as percent of native pulmonary artery. b, Collagen assay is expressed as percent of
native pulmonary artery.
% Collagen 5
Tissue-engineered collagen content 3 100
Native pulmonary artery collagen
c, Calcium content (ortho-cresolphthalein complex on method) is expressed as milligrams per gram of dry
tissue. d, DNA assay.
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ultimately leaving only the engineered tissue with-
out foreign material. The remaining cells and matrix
have the potential to remodel and organize into
functional tissue that can be used for reconstructive
or transplantation operation.24, 25 This approach of
creating tissue from autologous cells offers many
potential advantages. It eliminates the problems of
rejection and donor organ scarcity. Our results have
demonstrated evidence of functional endothelial
cells and viable fibroblasts in these implanted con-
duits. We have previously demonstrated that cells in
tissue-engineered valve leaflets have the capacity to
generate collagen, elastic fibers, factor VIII, and
attained mechanical properties resembling native
tissue.3 The conduit vessels in this study appear to
be viable structures that may have the potential for
greater durability because they could use naturally
existing mechanisms for repair and remodeling. The
problems associated with foreign body reaction and
the need for long-term anticoagulation can also be
eliminated. Finally, they appear to even possess the
potential for growth, which is of unique significance
in the pediatric population.
In previous studies replacing one pulmonary valve
leaflet in a lamb model, we have shown that the
cultured cells seeded in vitro onto the bioabsorbable
polymer could maintain their biologic activities in
vivo. With cell tracing, we have demonstrated that
the in vitro–labeled cells were traced within the
matrix even after the complete degradation of the
polymer scaffold. By contrast, implanted polymer
without cell seeding disappears completely over
time, suggesting that the presence of seeded cells
was a critical part of the tissue generation process.
This finding suggests that in vitro cell seeding is
necessary to engineer new tissue. In addition, in the
current experiments the control animal that under-
went PA replacement using polymer tube without
Fig. 6. Gross appearance of tissue-engineered conduit. a and b, Group A, 122 days after implantation. c
and d, Group V, 135 days after implantation. e, Control conduit. Note progressive thrombus formation on
the luminal surface of the conduit. Diameter of the conduit is also decreased.
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cells had severe thrombus formation develop, lead-
ing to pulmonary stenosis. This finding suggests that
cell seeding is also necessary to prevent the forma-
tion of thrombus on the luminal surface of conduit.
The possibility exists that recipient cell migration
from the adjacent native vessel onto the polymer
could also contribute to tissue formation, and circu-
lating endothelial cells have also been hypothesized
to be important in neoendothelialization after en-
dothelial injury.26 These circulating endothelial cells
might attach to the luminal surface, and seeded cells
might support the endothelial cells to grow quicker.
Our results with tissue-engineered valve leaflets and
labeled endothelial cells suggests that most of the
cells in the tissue-engineered structures are those
resulting from in vitro seeding.4
Previous studies have also confirmed that the use
of allogenic arterial cells or autologous dermal
fibroblasts would result in early graft failure, prob-
ably because of rejection and tissue contraction,
respectively. This study has shown that venous fibro-
blasts and endothelial cells have no demonstrable
histologic or morphologic differences from arterial
wall cells. Whether this is due to the short-term
follow-up of this study or to the alterations of
cellular phenotypes after in vitro expansion remain
to be determined. Although the DNA content stud-
ies suggested decreasing cell numbers with time, it is
not entirely clear that this represents “maturation”
of the tissue in the true sense.
These early results with tissue-engineered pulmo-
nary conduits appears promising, although many
issues remain to be addressed. The longer term
physiologic and growth characteristics of these im-
planted constructs clearly require further investiga-
tion. Nevertheless, the creation of a conduit from
autologous cells that seem to be viable structures is
a potentially important breakthrough in this field.
Construction of the most physiologic and natural
PA, using the principles and methods of TE, has the
potential for an important impact in the manage-
ment of patients with congenital heart disease.
Fig. 7. Miller’s elastic staining confirmed the presence of elastic fibers (black staining material) and
collagen fibers in the constructed conduit. a, Tissue-engineered conduit after 4 months of implantation in
group A (original magnification 350). b, Junction between tissue-engineered conduit and native
pulmonary artery (PA) (original magnification 350). c, Tissue-engineered conduit in group V (original
magnification 3100). d, Tissue-engineered conduit in group V (original magnification 3200).
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Several limitations still must be overcome before
the clinical application of these tissue-engineered
pulmonary arterial conduits will be possible. An
ideal conduit suitable for clinical application should
have not only growth potential and nonthromboge-
nicity but it also should have other characteristics
such as flexibility, lack of bulkiness, ease of passing
sutures, and low porosity. A major limitation of the
current biodegradable polymer is its stiffness before
in vivo implantation. The optimal duration of in
vitro seeding remains to be determined because
prolonged incubation will result in the degradation
of the bioabsorbable polymer. On the other hand,
the composite polymer will remain too stiff and
nonpliable for surgical manipulation if implanted
prematurely. No visible calcification was observed in
any tissue-engineered conduit. More long-term fol-
low-up is necessary to determine whether the in-
creased DNA content represents a transient active
cellular metabolism or the ultimate development of
Fig. 8. Positive factor VIII staining (red) from the endothelial cells were identified along the luminal
surface of tissue-engineered conduit. a, Group A (original magnification 3100). b, Group V (original
magnification 3200).
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atherosclerotic calcification. Active experimental re-
search to develop a flexible elastic polymer in this
field is currently underway at this institution.
We gratefully acknowledge ChemoSero-Therapeutic
Research Institute, Japan, for providing the pasteurized
fibrin glue.
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Discussion
Dr. John H. Kennedy (Cambridge, United Kingdom). I
have only one small question. In presenting a tissue
substitute for the native PA, notably lacking in your
presentation was the presence or absence of the proteo-
glycan fraction, the highly negative charged molecules,
where presumably early calcification triggered by perhaps
galactosidase proteins and osteopontin bring about the
clinical problem that we are all trying to approach. I
wonder whether the increase in calcium without the
evidence of calcification is because the proteoglycan moi-
ety is absent in your experimental model?
Dr. Shinoka. Thank you for your comments. We did not
specifically investigate the presence or absence of proteo-
glycan fraction in this study. Obviously, this is an initial
study to test the feasibility of TE of vascular conduits.
There are many questions remaining to be answered,
especially at the molecular level. At present, the actual
meaning of the elevated calcium level in the tissue-
engineered graft is not yet determined. However, in a
previous study using dermal fibroblasts instead of arterial
wall cells in valve leaflets demonstrated macroscopic
calcification and stenosis. In these dermal fibroblast con-
structs, calcium content was more than 100 mg/gm dry
tissue. Your point is very well taken, and I believe more
long-term studies and more sophisticated molecular anal-
yses will be very important.
Dr. Edward D. Verrier (Seattle, Wash.). I have three
questions. Number one, is the evidence of growth any-
thing other than dilatation when the scaffolding absorbs?
Number two, are there smooth muscle cells present? If
you use endothelial cells, I would imagine you might get a
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significant proliferation of smooth muscle cells. Is that
present?
And the third question is: What are the vascular
properties of these endothelial or smooth muscle cells?
Does the conduit vasodilate or vasoconstrict? Do you
think that it is going to have an intimal hyperplastic
response based on its vascular biology? Is any of that
known?
Dr. Shinoka. With respect to your first question, it is
always difficult to differentiate dilatation versus growth.
However, there are several clues that suggest the latter.
First, the diameter of tissue-engineered graft increased in
proportion to the native PA. Second, the DNA contents
that reflected cell numbers were higher than the native PA
at 6 months while the diameter was increased. In simple
dilatation, one would expect an increase in diameter
without increase in cell numbers. Third, at the histologic
level, the collagen content and elastic fibers did not
resemble those of simple dilatation. Therefore you may
call it growth or dilatation. The point is that the tissue-
engineered graft behaved closely like the adjacent native
PA.
Regarding the smooth muscle cells, we did not observe
any significant overproliferation in this large vessel study,
but that might be related to the low-pressure system at the
pulmonary circulation. We did observe this problem in
small arterial grafts subjected to systemic arterial pres-
sure. We believe that many cell-to-cell interactions and
signals will affect this cellular growth pattern and the
formation of intimal hyperplasia. Further investigations
are underway to try to improve the current polymer, cell
seeding methods, and in vitro preconditioning in an
attempt to overcome this challenging problem.
Finally, we did not investigate the vascular properties of
these tissue-engineered grafts in this particular study, It is
hoped that we will be able to answer this question in the
next study in which we are trying to create a tissue-
engineered aorta.
Dr. Ludwig K. von Segesser (Lausanne, Switzerland).
Did you observe tight junctions in your explants?
Dr. Shinoka. I think you raised a very important
question with respect to the ultrastructure of these tissue-
engineered vascular conduits. Unfortunately, we did not
look at these specimens at the electron microscopic level.
We hope this study will stimulate more investigators and
enthusiasm to test this TE concept at various levels.
And regarding the calcification, we did recognize the
increase in the calcium content in our tissue. However, we
did some pilot study using abdominal fibroblast instead of
the arterial wall cells. In such a case, calcium content was
more than 100 ml/gm tissue. So in this arterial and venous
cell origin conduit the calcium accumulation is very trivial.
Even though, I think longer follow-up would be necessary
to confirm the calcification of our TE conduit.
Dr. Mayer. In response to Dr. Kennedy’s question, we
simply have not looked at the proteoglycan content to
know whether or not that is playing a role in the devel-
opment of these tissues. You have to understand this was
a feasibility sort of study. I think we are encouraged both
from this work and the work that we have done with valve
leaflets using very similar approaches. There are a lot of
hurdles to be jumped here. The polymer is really not very
good in its current form. It is very stiff, it is very difficult to
work with. When we tried to replace all three leaflets, for
instance, in the pulmonary valve, the animal had pulmo-
nary valvular stenosis.
Our colleagues at MIT, Dr. Robert Langer and his
group, have now been supplying us with a flexible poly-
mer, which we hope will get over some of those technical
problems. We have an enormous amount of work to do.
We have to go back and try to understand the science of
what is happening in these structures, what genes we are
turning on in the endothelial cells and the smooth muscle,
and how cells are interacting. We have unresolved ques-
tions about whether we should seed the polymer with
mixed cell cultures or whether we should serially seed it
with myofibroblasts first, followed by endothelial cells
second.
We do have experience in trying to make small arterial
grafts that Dr. Verrier was alluding to, I think, when he
was asking the question about fibrous intimal hyperplasia.
In fact, fibrous intimal hyperplasia does occur when you
try to use this same kind of approach in a femoral artery
graft. I do not want anyone to think that we are going to
have something ready to go into patients in the next year.
But we think this is exciting work. We continue to be
enthusiastic about it.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
5 4 6 Shinoka et al.
